Quince Therapeutics, Inc.
QNCX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $77,032 | $58,442 | $80,900 |
| - Cash | $6,452 | $16,826 | $7,771 | $6,212 |
| + Debt | $359 | $17,376 | $15,751 | $14,811 |
| Enterprise Value | – | $77,582 | $66,422 | $89,499 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$36 | -$35 | $0 | -$16 |
| % Margin | – | – | – | – |
| EBITDA | -$13,452 | -$15,947 | -$12,902 | -$12,435 |
| % Margin | – | – | – | – |
| Net Income | -$13,442 | -$16,049 | -$15,030 | -$12,458 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.25 | -0.34 | -0.34 | -0.28 |
| % Growth | 26.5% | 0% | -21.4% | – |
| Operating Cash Flow | -$9,928 | -$11,415 | -$9,601 | -$7,552 |
| Capital Expenditures | -$74 | -$126 | -$148 | -$133 |
| Free Cash Flow | -$10,002 | -$11,541 | -$9,749 | -$7,685 |